Please use this identifier to cite or link to this item:
|Title:||Duloxetine in the acute and continuation treatment of major depressive disorder.|
|Authors:||Bochsler, Lanny;Olver, James S;Norman, Trevor R|
|Affiliation:||Department of Psychiatry, University of Melbourne, Austin Hospital, Heidelberg, Victoria 3084, Australia.|
|Citation:||Expert Review of Neurotherapeutics; 11(11): 1525-39|
|Abstract:||Duloxetine is a serotonin-noradrenaline reuptake inhibitor with indications for use in the short term, continuation and maintenance treatment of major depression. Although clinicians currently have access to a range of medications for the treatment of depression, a significant number of patients fail to respond or remit from their illness despite adequate trials of treatment with multiple agents. A developing concept is that antidepressant strategies that combine multiple mechanisms of action may have advantages over agents with single mechanisms (i.e., selective serotonin reuptake inhibitors). As a dual-acting agent, duloxetine offers the promise of advantages in terms of efficacy over selective serotonin reuptake inhibitors while retaining a favorable safety and tolerability profile in comparison to older agents. Likewise, duloxetine is of interest in the treatment of certain conditions commonly seen in conjunction with major depression, particularly anxiety and pain, both of which may respond more favorably to agents that act on both serotonin and noradrenaline neurotransmitter systems.|
|Internal ID Number:||22014130|
|Subjects:||Antidepressive Agents.pharmacology.therapeutic use|
Clinical Trials as Topic
Depressive Disorder, Major.drug therapy
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.